 Using this technology scientists aims to create ADCs having an optimal therapeutic window, balancing the effect of potent cell-killing agents on tumor cells versus healthy cells.The synthetic analogs of duocarmycins include adozelesin, bizelesin, and carzelesin.As members of the cyclopropylpyrroloindole family, these investigational drugs have progressed into clinical trials for the treatment of cancer.